{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:38:16Z","timestamp":1773707896724,"version":"3.50.1"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.pbb.2024.173804","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T16:55:47Z","timestamp":1717779347000},"page":"173804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["From past to future: 50\u00a0years of pharmacological interventions to treat narcolepsy"],"prefix":"10.1016","volume":"241","author":[{"given":"Eric","family":"Konofal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2024.173804_bb0005","series-title":"De l\u2019emploi th\u00e9rapeutique de la Quassine pr\u00e9par\u00e9e par M","author":"Adrian","year":"1887"},{"key":"10.1016\/j.pbb.2024.173804_bb0010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0140-6736(91)92966-6","article-title":"Mazindol in long-term treatment of narcolepsy","volume":"337","author":"Alvarez","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173804_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129151","article-title":"Design and synthesis of novel orexin 2 receptor agonists with a 1, 3, 5-trioxazatriquinane skeleton","volume":"82","author":"Amezawa","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2024.173804_bb0020","series-title":"Pharmaceutical Compositions and Methods for Stimulating H3 Histamine Receptors","author":"Arrang","year":"1988"},{"key":"10.1016\/j.pbb.2024.173804_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00455978","article-title":"The effect of methylphenidate on the sleep cycle in man","volume":"10","author":"Baekeland","year":"1966","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.pbb.2024.173804_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neurol.2023.08.001","article-title":"Narcolepsies, update in 2023","volume":"179","author":"Barateau","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.pbb.2024.173804_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.1910.sp001392","article-title":"Chemical structure and sympathomimetic action of amines","volume":"41","author":"Barger","year":"1910","journal-title":"J. Physiol."},{"issue":"15","key":"10.1016\/j.pbb.2024.173804_bb0040","first-page":"1330","article-title":"Traitement des hypersomnies par le modafinil","volume":"1983","author":"Bastuji","year":"1986","journal-title":"Presse Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0045","first-page":"1312","article-title":"\u00c9tude experimentale de l\u2019abaissement de la vigilance par la gamma-butyrolactone","volume":"251","author":"Benda","year":"1960","journal-title":"Comptes Rendus Hebd. S\u00e9ances Acad\u00e9mie Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/jm100064d","article-title":"Histamine H3 receptor as a drug discovery target","volume":"54","author":"Berlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0055","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1523\/JNEUROSCI.4187-12.2013","article-title":"Increased agonist affinity at the \u03bc-opioid receptor induced by prolonged agonist exposure","volume":"33","author":"Birdsong","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173804_bb0060","first-page":"730","article-title":"Clinical experiences with sodium beta, beta-pentamethylene-gamma-hydroxybutyrate (go 186, W1597), a new type of activating substance","volume":"55","author":"Bochnik","year":"1960","journal-title":"Med. Klin."},{"key":"10.1016\/j.pbb.2024.173804_bb0065","first-page":"100","article-title":"Psychopharmacologie exp\u00e9rimentale et pr\u00e9vision de l\u2019activit\u00e9 des substances psychotropes","author":"Boissier","year":"1968","journal-title":"Clinical Psychopharmacology. Karger Publishers"},{"key":"10.1016\/j.pbb.2024.173804_bb0070","series-title":"\u00dcber Weckamine: Pervitin und Bezedrin: Monographien aus dem Gesamtgebiete der Neurologie und Psychiatrie [\u00c0 propos des weckamines: pervitine et benz\u00e9drine: monographies des grands domaines de la neurologie et la psychiatrie]","author":"Bonhoff","year":"1954"},{"key":"10.1016\/j.pbb.2024.173804_bb0075","series-title":"A propos des psychotoniques levophac\u00e9top\u00e9rane et m\u00e9thylph\u00e9nidate dans les psychoses et dans les \u00e9tats psychon\u00e9vrotiques mineurs","author":"Bontronc","year":"1961"},{"key":"10.1016\/j.pbb.2024.173804_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.1.5750.670-c","article-title":"Treatment of narcolepsy","volume":"1","author":"Bourdillon","year":"1971","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pbb.2024.173804_bb0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1351\/pac196306030385","article-title":"D\u00e9veloppements r\u00e9cents de la psychopharmacologie","volume":"6","author":"Bovet","year":"1963","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0090","first-page":"211","article-title":"Gamma-hydroxybutyrate in the treatment of compound narcolepsy","volume":"4","author":"Broughton","year":"1975","journal-title":"Sleep Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0317167100119304","article-title":"The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate","volume":"6","author":"Broughton","year":"1979","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jlac.18611200308","article-title":"Bildung einer zuckerartigen Substanz durch Synthese","volume":"120","author":"Butlerow","year":"1861","journal-title":"Justus Liebigs Ann. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0105","first-page":"A1","article-title":"2-(2-aminophenoxy)-3-chloronaphthalene-1, 4-dione compounds having orexin 2 receptor agonist activity","volume":"2014198880","author":"Cano","year":"2014","journal-title":"WO Patent"},{"key":"10.1016\/j.pbb.2024.173804_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00500964","article-title":"Effects of mazindol, fenfluramine and chlorimipramine on the 5-hydroxytryptamine uptake and storage mechanisms in rat brain: similarities and differences","volume":"300","author":"Carruba","year":"1977","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0115","series-title":"FDA Drug Approval Package: Wakix (pitolisant) (No. Application Number: 211150Orig1s000)","author":"Center for Drug Evaluation and Research","year":"2019"},{"key":"10.1016\/j.pbb.2024.173804_bb0120","series-title":"Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease","author":"Ciccone","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0125","series-title":"Takeda\u2019s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial among Healthy Men","author":"Ciccone","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0130","series-title":"Preclinical Data Shows Significant Efficacy with Low-Dose of ORX750 for Narcolepsy","author":"Ciccone","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1590\/S1516-44462009000100004","article-title":"Prevalence of the HLA-DQB1* 0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in S\u00e3o Paulo","volume":"31","author":"Coelho","year":"2009","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173804_bb0140","series-title":"Controlled Release Pharmaceutical Compositions Based on One or more Pharmaceutically Acceptable Salts of Gamma Hydroxy-Butyric Acid","author":"Conte","year":"1997"},{"key":"10.1016\/j.pbb.2024.173804_bb0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neubiorev.2015.03.012","article-title":"Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1, 4-butanediol (1, 4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use","volume":"53","author":"Corkery","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2024.173804_bb0150","first-page":"515","article-title":"Congestive cardiomyopathy in addiction to clobenzorex, an anorexigenic drug","volume":"79","author":"Cornaert","year":"1986","journal-title":"Arch. Mal. Coeur Vaiss."},{"key":"10.1016\/j.pbb.2024.173804_bb0155","first-page":"620","article-title":"The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report","volume":"31","author":"Daly","year":"1956","journal-title":"Proc. Staff Meet. Mayo Clin."},{"key":"10.1016\/j.pbb.2024.173804_bb0160","series-title":"Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1","author":"Dauvilliers","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s000180050446","article-title":"The hypocretins\/orexins: novel hypothalamic neuropeptides involved in different physiological systems","volume":"56","author":"De Lecea","year":"1999","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"10.1016\/j.pbb.2024.173804_bb0170","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/dta.2142","article-title":"Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog","volume":"9","author":"Dowling","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.pbb.2024.173804_bb0175","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jama.1931.02720430020006","article-title":"Symptomatic treatment for narcolepsy","volume":"96","author":"Doyle","year":"1931","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173804_bb0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1932.02730330024006","article-title":"Narcolepsy: results of treatment with ephedrine sulphate","volume":"98","author":"Doyle","year":"1932","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173804_bb0185","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/bja\/26.5.357","article-title":"A review of chlorpromazine hydrochloride","volume":"26","author":"Dundee","year":"1954","journal-title":"BJA Br. J. Anaesth."},{"key":"10.1016\/j.pbb.2024.173804_bb0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(79)90033-5","article-title":"A possible \u03b1-adrenergic mechanism for drug (CRL 40028)-induced hyperactivity","volume":"59","author":"Duteil","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-2999(90)90591-S","article-title":"Central \u03b11-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals","volume":"180","author":"Duteil","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0200","first-page":"262","article-title":"Treatment of narcolepsy with desoxyephedrine hydrochloride","author":"Eaton","year":"1943","journal-title":"Proc. Staff Meet. Mayo Clin."},{"key":"10.1016\/j.pbb.2024.173804_bb0205","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cber.188702001142","article-title":"Ueber einige derivate der Phenylmethacryls\u00e4ure und der Phenylisobutters\u00e4ure [about some phenylmethacrylic acid and phenylisobuttiric acid derivatives]","volume":"20","author":"Edeleanu","year":"1887","journal-title":"Chem. Ber."},{"key":"10.1016\/j.pbb.2024.173804_bb0210","first-page":"327","article-title":"Impromidine-analogous guanidines: synthesis and activity at the histamine H2-receptor. 29","volume":"38","author":"Elz","year":"1988","journal-title":"Histamine analogs. Arzneimittelforschung."},{"key":"10.1016\/j.pbb.2024.173804_bb0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1054-3589(08)60234-3","article-title":"Effect of amphetamine-type psychostimulants on brain metabolism","volume":"13","author":"Estler","year":"1975","journal-title":"Adv. Pharmacol. Chemother."},{"key":"10.1016\/j.pbb.2024.173804_bb0220","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1192\/bjp.112.485.401","article-title":"Some experiments in the chemistry of narcoleptic sleep","volume":"112","author":"Evans","year":"1966","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173804_bb0225","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pbb.2024.173804_bb0230","first-page":"10","article-title":"Clinical experience with meratran: a new central nervous system stimulant","volume":"16","author":"Fabing","year":"1955","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.pbb.2024.173804_bb0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0025-7125(16)34440-6","article-title":"The newer analeptic drugs","volume":"41","author":"Fabing","year":"1957","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.pbb.2024.173804_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003270","article-title":"ImmunoChip study implicates antigen presentation to T cells in narcolepsy","volume":"9","author":"Faraco","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.pbb.2024.173804_bb0245","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0024-3205(98)00107-6","article-title":"Molecular mechanisms of G protein-coupled receptor desensitization and resensitization","volume":"62","author":"Ferguson","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb7500","series-title":"L'adrafinil: Etude Pharmacochimique","author":"Foe","year":"1987"},{"key":"10.1016\/j.pbb.2024.173804_bb0250","series-title":"Principes de th\u00e9rapeutique g\u00e9n\u00e9rale, ou le m\u00e9dicament \u00e9tudi\u00e9 aux points de vue physiologique, posologique et clinique","author":"Fonssagrives","year":"1875"},{"key":"10.1016\/j.pbb.2024.173804_bb0255","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2024.173804_bb0260","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2024.173804_bb0265","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/243518a0","article-title":"Acetylcholine release within the cat striatum during the sleep-wakefulness cycle","volume":"243","author":"Gadea-Ciria","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173804_bb0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.neuro.27.070203.144206","article-title":"Desensitization of G protein\u2013coupled receptors and neuronal functions","volume":"27","author":"Gainetdinov","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2024.173804_bb0275","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","article-title":"Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome","volume":"334","author":"Gallimberti","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173804_bb0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/(SICI)1521-4184(199812)331:12<395::AID-ARDP395>3.0.CO;2-7","article-title":"Synthesis of potent non-imidazole histamine H3-receptor antagonists","volume":"331","author":"Ganellin","year":"1998","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.pbb.2024.173804_bb0285","first-page":"1549","article-title":"R\u00e9sultats obtenus avec le 8.228 R.P. apr\u00e8s deux ans d\u2019utilisation de ce psychotonique","volume":"94","author":"Garde","year":"1962","journal-title":"Lyon Med."},{"issue":"79","key":"10.1016\/j.pbb.2024.173804_bb0290","first-page":"626","article-title":"De la narcolepsie I","volume":"53","author":"G\u00e9lineau","year":"1880","journal-title":"Gaz. H\u00f4p. Civ. Mil."},{"key":"10.1016\/j.pbb.2024.173804_bb0295","first-page":"635","article-title":"De la narcolepsie II","volume":"53","author":"G\u00e9lineau","year":"1880","journal-title":"Gaz. H\u00f4p. Civ. Mil."},{"key":"10.1016\/j.pbb.2024.173804_bb0300","series-title":"Maladie et hygi\u00e8ne des gens nerveux","author":"G\u00e9lineau","year":"1893"},{"key":"10.1016\/j.pbb.2024.173804_bb0305","series-title":"De la narcolepsie","author":"G\u00e9lineau","year":"1881"},{"key":"10.1016\/j.pbb.2024.173804_bb0310","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1523\/JNEUROSCI.21-18-07273.2001","article-title":"Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat","volume":"21","author":"Gerashchenko","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173804_bb0315","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0306-4522(02)00575-4","article-title":"Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in long-Evans rats","volume":"116","author":"Gerashchenko","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2024.173804_bb0320","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/0024-3205(66)90261-X","article-title":"Selective increase of brain dopamine induced by gamma-hydroxybutyrate","volume":"5","author":"Gessa","year":"1966","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0325","first-page":"285","article-title":"Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4\u2032-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol)","volume":"214","author":"Gogerty","year":"1975","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.pbb.2024.173804_bb0330","first-page":"25","article-title":"Chemistry and pharmacology of mazindol","volume":"15","author":"Gogerty","year":"1976","journal-title":"Triangle Sandoz J. Med. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0335","series-title":"Quoted in Torregrossa, 1996","author":"Goldenberg","year":"1987"},{"key":"10.1016\/j.pbb.2024.173804_bb0340","first-page":"65","article-title":"Traitement de la somnolence diurne excessive","volume":"8","author":"Goldenberg","year":"1998","journal-title":"Lett. Neurol."},{"key":"10.1016\/j.pbb.2024.173804_bb0345","first-page":"424","article-title":"Quantitative EEG analysis of stimulant properties of histamine and histamine derivatives","volume":"22","author":"Goldstein","year":"1963","journal-title":"Fed. Proc."},{"key":"10.1016\/j.pbb.2024.173804_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1360-0443.1972.tb01166.x","article-title":"Subjective effects of two anorexigenic agents fenfluramine and AN 448 in amphetamine-dependent subjects","volume":"67","author":"G\u00f6testam","year":"1972","journal-title":"Br. J. Addict. Alcohol Other Drugs"},{"key":"10.1016\/j.pbb.2024.173804_bb0355","series-title":"Handbook of Neurochemistry","article-title":"Histamine","author":"Green","year":"1970"},{"key":"10.1016\/j.pbb.2024.173804_bb0360","series-title":"Narcolepsy: Proceedings of the First International Symposium on Narcolepsy, July 1975, Montpellier","author":"Guilleminault","year":"1976"},{"key":"10.1016\/j.pbb.2024.173804_bb0365","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0014-2999(70)90018-X","article-title":"Effect of hemicholinium-3 on slow wave and paradoxical sleep of cat","volume":"11","author":"Hazra","year":"1970","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/BF02244069","article-title":"Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration","volume":"103","author":"Hermant","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173804_bb0375","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0014-4886(67)90160-4","article-title":"Neurophysiology, phylogeny, and functional significance of dreaming","volume":"19","author":"Hern\u00e1ndez-Pe\u00f3n","year":"1967","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2024.173804_bb0380","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-2007-1019487","article-title":"An absolute must in clinico-pharmacological research: pharmaco-electroencephalography, its possibilities and limitations","volume":"16","author":"Herrmann","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2024.173804_bb0385","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.foodchem.2015.06.093","article-title":"Monitoring of twenty-two sulfonamides in edible tissues: investigation of new metabolites and their potential toxicity","volume":"192","author":"Hiba","year":"2016","journal-title":"Food Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0390","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0022-510X(66)90001-3","article-title":"Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran)","volume":"3","author":"Hishikawa","year":"1966","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0395","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cber.18710040271","article-title":"Methylirung der Phenylgruppe im Anilin","volume":"4","author":"Hofmann","year":"1871","journal-title":"Ber. Dtsch. Chem. Ges."},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2024.173804_bb0400","first-page":"183","article-title":"Subjective effects of two anorexigenic agents--fenfluramine and AN 448 in normal subjects","volume":"51","author":"Holmstrand","year":"1975","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.pbb.2024.173804_bb0405","unstructured":"Houlihan, W.J., 1967. 9b-phenyl-1, 2, 3, 9b-tetrahydro-5h-imidazo [2, 1-a] isoindol-5-ones. US Patent 3,334,113. in Letters, Notes, and Answers, 1910. - Br Med J 1910 Oct 8225971103-4."},{"key":"10.1016\/j.pbb.2024.173804_bb0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.122.001449","article-title":"TAK-994, a novel orally available brain-penetrant orexin 2 receptor-selective agonist, suppresses fragmentation of wakefulness and cataplexy-like episodes in mouse models of narcolepsy","volume":"385","author":"Ishikawa","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173804_bb0415","first-page":"60","article-title":"D-Desoxyephedrine: a review","volume":"3","author":"Ivy","year":"1943","journal-title":"War Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0420","first-page":"278","article-title":"Symptomatische Behandlung der pathologischen Schlafsucht, besonders der Narkolepsie","volume":"27","author":"Janota","year":"1931","journal-title":"Med. Klin."},{"key":"10.1016\/j.pbb.2024.173804_bb0425","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1126\/science.172.3983.601","article-title":"Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep","volume":"172","author":"Jasper","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.pbb.2024.173804_bb0430","series-title":"Examination of potential addictive effects of NLS-3, a new compound in development for ADHD - 4th. EUNETHYDIS International Conference on ADHD, Berlin, Germany, 16th\u201319th October 2016","author":"Jean-Charles Bizot","year":"2016"},{"key":"10.1016\/j.pbb.2024.173804_bb0435","first-page":"23","article-title":"Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs","volume":"3","author":"John","year":"2000","journal-title":"Sleep Res. Online SRO"},{"key":"10.1016\/j.pbb.2024.173804_bb0440","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-642-95201-2_10","article-title":"Some monoaminergic mechanisms controlling sleep and waking","author":"Jouvet","year":"1972","journal-title":"Brain Hum. Behav."},{"key":"10.1016\/j.pbb.2024.173804_bb0445","series-title":"Journ\u00e9es d\u2019\u00e9tude Sur Le Vieillissement, Organis\u00e9es Par l\u2019ORPHEM, Marseilles, France. Marseilles, France","article-title":"Une nouvelle famille de m\u00e9dicaments pour am\u00e9liorer l\u2019\u00e9veil: les eugr\u00e9goriques","author":"Jouvet","year":"1987"},{"key":"10.1016\/j.pbb.2024.173804_bb0450","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","article-title":"The European medicines agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for human use","volume":"33","author":"Kollb-Sielecka","year":"2017","journal-title":"Sleep Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0455","series-title":"Lauflumide and the Enantiomers Thereof, Method for Preparing Same and Therapeutic Uses Thereof","author":"Konofal","year":"2017"},{"key":"10.1016\/j.pbb.2024.173804_bb0460","series-title":"ADHD and its Medications, an Illustrated History over Time","author":"Konofal","year":"2019"},{"key":"10.1016\/j.pbb.2024.173804_bb0465","series-title":"Phacetoperane for Treating of Attention Deficit Hyperactivity Disorder","author":"Konofal","year":"2019"},{"key":"10.1016\/j.pbb.2024.173804_bb0470","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.msom.2012.01.005","article-title":"Mazindol: an alternative in the treatment of awakening disorders and attention deficit? | Le mazindol: Une alternative dans le traitement des troubles de l\u2019\u00e9veil et du maintien de l\u2019attention\u00a0? Med","volume":"9","author":"Konofal","year":"2012","journal-title":"Sommeil"},{"key":"10.1016\/j.pbb.2024.173804_bb0475","article-title":"NLS-3 (levophacetoperane or (R, R) phacetoperane): a reverse ester of methylphenidate: a literature review","author":"Konofal","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0480","series-title":"W26. First dual non-sulfonamide OX1R and OX2R agonists and their potential use for the treatment or prevention of neurological diseases","author":"Konofal","year":"2024"},{"key":"10.1016\/j.pbb.2024.173804_bb0485","series-title":"T22. Neuroprotective effect of mazindol on nocturnal activity in an Orexin-B-Saporin-induced narcoleptic-like model in Sprague-Dawley rats","author":"Konofal","year":"2024"},{"key":"10.1016\/j.pbb.2024.173804_bb0490","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ng.734","article-title":"Common variants in P2RY11 are associated with narcolepsy","volume":"43","author":"Kornum","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pbb.2024.173804_bb0495","first-page":"704","article-title":"Agonist induced homologous desensitization of \u03bc-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy","volume":"54","author":"Kovoor","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0500","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1113\/jphysiol.1943.sp004011","article-title":"Histamine in nervous tissue","volume":"102","author":"Kwiatkowski","year":"1943","journal-title":"J. Physiol."},{"key":"10.1016\/j.pbb.2024.173804_bb0505","first-page":"1216","article-title":"220 cases of anesthesia in neurosurgery with sodium 4-hydroxybutyrate","volume":"69","author":"Laborit","year":"1961","journal-title":"Presse Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0510","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1254\/jjp.27.491","article-title":"Dualist or pseudo-dualist interactions of mepyramine, diphenhydramine and eprozinol with histamine at H1-receptors","volume":"27","author":"Labrid","year":"1977","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0515","series-title":"Therapeutic Composition Containing a Mandelamidine Derivative","author":"Lafon","year":"1971"},{"key":"10.1016\/j.pbb.2024.173804_bb0520","series-title":"Nouvelle composition pharmaceutique dou\u00e9e de propri\u00e9t\u00e9s anorexique","author":"Lafon","year":"1962"},{"key":"10.1016\/j.pbb.2024.173804_bb0525","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/sleep\/13.5.441","article-title":"Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of rhesus monkeys","volume":"13","author":"Lagarde","year":"1990","journal-title":"Sleep"},{"key":"10.1016\/j.pbb.2024.173804_bb0530","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5664\/jcsm.6500","article-title":"Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study","volume":"13","author":"Lecendreux","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0535","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1749-6632.1957.tb49682.x","article-title":"Clinical toxicity of sulfonamides","volume":"69","author":"Lehr","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb4000","series-title":"La Semaine des Hopitaux: Organe Fonde par L'association D'enseignement Medical des Hopitaux de Paris","first-page":"336","article-title":"The value of phacetoperan in the treatment of obesity","volume":"38","author":"Leprat","year":"1962"},{"key":"10.1016\/j.pbb.2024.173804_bb0540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-8707(46)90004-4","article-title":"\u03b2-Dimethylaminoethyl benzhydryl ether hydrochloride (Benadryl) its use in allergic diseases","volume":"17","author":"Levin","year":"1946","journal-title":"J. Allergy"},{"key":"10.1016\/j.pbb.2024.173804_bb0545","first-page":"452","article-title":"[125I] iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors","volume":"271","author":"Ligneau","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173804_bb0550","first-page":"658","article-title":"Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist","volume":"287","author":"Ligneau","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173804_bb0555","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0006-8993(92)91713-O","article-title":"Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat","volume":"591","author":"Lin","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0560","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.pbb.2024.173804_bb0565","first-page":"816,929","article-title":"Process for beta-diethylaminopropiophenone","volume":"2","author":"Lobby","year":"1957","journal-title":"US Patent"},{"key":"10.1016\/j.pbb.2024.173804_bb0570","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fnins.2018.00519","article-title":"Lauflumide (NLS-4) is a new potent wake-promoting compound","volume":"12","author":"Luca","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2024.173804_bb0575","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1037\/h0082897","article-title":"Effect of amphetamine on the detectability of signals in a vigilance task","volume":"19","author":"Mackworth","year":"1965","journal-title":"Can. J. Psychol. Can. Psychol."},{"key":"10.1016\/j.pbb.2024.173804_bb0580","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/17470214808416738","article-title":"The breakdown of vigilance during prolonged visual search","volume":"1","author":"Mackworth","year":"1948","journal-title":"Q. J. Exp. Psychol."},{"key":"10.1016\/j.pbb.2024.173804_bb0585","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.conb.2013.04.013","article-title":"The autoimmune basis of narcolepsy","volume":"23","author":"Mahlios","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.pbb.2024.173804_bb0590","series-title":"La coca et ses applications th\u00e9rapeutiques","author":"Mariani","year":"1888"},{"key":"10.1016\/j.pbb.2024.173804_bb0595","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0028-1094603","article-title":"Pharmaco-electroencephalography: the value of quantified EEG in psychopharmacology","volume":"12","author":"Matejcek","year":"1979","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2024.173804_bb0600","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.146.3649.1328","article-title":"Paradoxical phase of sleep: its artificial induction in the cat by sodium butyrate","volume":"146","author":"Matsuzaki","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.pbb.2024.173804_bb0605","series-title":"Clinical Improvements in Cataplexy Seen through Mazindol Extended-Release Treatment","author":"Meglio","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0610","series-title":"Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings","author":"Meglio","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0615","first-page":"372","article-title":"The effect of adrafinil on the nocturnal activity of the rhesus monkey (Macaca mulatta)","volume":"16","author":"Milhaud","year":"1985","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0620","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/sleep\/16.3.203","article-title":"The treatment of excessive somnolence with stimulant drugs","volume":"16","author":"Mitler","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.pbb.2024.173804_bb0625","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF02142244","article-title":"The waking action of histamine","volume":"23","author":"Monnier","year":"1967","journal-title":"Experientia"},{"key":"10.1016\/j.pbb.2024.173804_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2024.173804_bb0635","series-title":"In-Vitro Metabolism Studies with BLX-1026, a Novel Orexin-2 Agonist with Anti-Obesity Activity","author":"Mukherjee","year":"2008"},{"key":"10.1016\/j.pbb.2024.173804_bb0640","first-page":"700","article-title":"Ephedra vulgaris rich","volume":"32","author":"Nagai","year":"1887","journal-title":"var. helvetica Hook. et Thomps. Pharm Ztg"},{"key":"10.1016\/j.pbb.2024.173804_bb0645","series-title":"Sulfonamide Derivative or Pharmaceutically Acceptable Acid Addition Salt Thereof","author":"Nagase","year":"2017"},{"key":"10.1016\/j.pbb.2024.173804_bb0650","series-title":"Novel Derivatives of Amino Acids for Treatment of Obesity and Related Disorders","author":"Neogi","year":"2008"},{"key":"10.1016\/j.pbb.2024.173804_bb0655","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.sleep.2004.11.007","article-title":"The association between narcolepsy and REM behavior disorder (RBD)","volume":"6","author":"Nightingale","year":"2005","journal-title":"Sleep Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0660","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00213-021-05779-x","article-title":"Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation","volume":"238","author":"Nirogi","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173804_bb0665","doi-asserted-by":"crossref","first-page":"A267","DOI":"10.1093\/sleep\/zsad077.0609","article-title":"0609 Samelisant, histamine 3 receptor agonist for the potential treatment of excessive daytime sleepiness in patients with narcolepsy","volume":"46","author":"Nirogi","year":"2023","journal-title":"Sleep"},{"key":"10.1016\/j.pbb.2024.173804_bb0670","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sleep.2012.07.008","article-title":"Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review","volume":"14","author":"Nittur","year":"2013","journal-title":"Sleep Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF01964877","article-title":"Cholinergic link in the histamine-mediated increase in homovanillic acid in the rat striatum","volume":"7","author":"Nowak","year":"1977","journal-title":"Agents Actions"},{"key":"10.1016\/j.pbb.2024.173804_bb0680","first-page":"825","article-title":"Electroencephalographic experimentation with 2 new activators: tocen and hexacyclonate (gevilon)","volume":"91","author":"Orioli","year":"1963","journal-title":"G. Psichiatr. Neuropatol."},{"key":"10.1016\/j.pbb.2024.173804_bb0685","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1192\/bjp.105.439.269","article-title":"Experimental studies of rhythm, anxiety and cerebral vigilance","volume":"105","author":"Oswald","year":"1959","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0690","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/bmj.2.5604.559-a","article-title":"Drugs and sleep","volume":"2","author":"Oswald","year":"1968","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pbb.2024.173804_bb0695","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/sleep\/16.3.201","article-title":"2. Amphetamine prescription","volume":"16","author":"Parkes","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.pbb.2024.173804_bb0700","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0404.1979.tb02976.x","article-title":"Mazindol in the treatment of narcolepsy","volume":"60","author":"Parkes","year":"1979","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.pbb.2024.173804_bb0705","first-page":"1967","article-title":"Donn\u00e9es actuelles sur le traitement de la narcolepsie, action des imipraminiques","volume":"92","author":"Passouant","year":"1970","journal-title":"Concours M\u00e9d."},{"key":"10.1016\/j.pbb.2024.173804_bb0710","first-page":"59","article-title":"Salzsaures Orexin, ein echtes Stomachicum","volume":"4","author":"Penzoldt","year":"1890","journal-title":"Ther. Monatschefte"},{"key":"10.1016\/j.pbb.2024.173804_bb0715","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173804_bb0720","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.1930.02710370034010","article-title":"Clinical observations on phenyl- aminoethanol sulphate","volume":"94","author":"Piness","year":"1930","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173804_bb0725","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13665","article-title":"The orexin story, sleep and sleep disturbances","volume":"31","author":"Pizza","year":"2022","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0730","series-title":"Note breve \u00e0 propos de l\u2019effet du gamma-hydroxybutyrate de sodium dans la turbulence nocturne, in: Agressologie. Masson, pp. R24-+","author":"Pougetoux","year":"1965"},{"key":"10.1016\/j.pbb.2024.173804_bb0735","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1001\/jama.1935.02760510023006","article-title":"The use of benzedrine for the treatment of narcolepsy","volume":"105","author":"Prinzmetal","year":"1935","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173804_bb0740","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1135\/cccc19550210","article-title":"Antihistamine substances. XXXVII. Synthetic antispasmodics. XI. Phosphonium salts. Comparison of the activity of various types of onium salts","volume":"20","author":"Protiva","year":"1955","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"10.1016\/j.pbb.2024.173804_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneurpsyc.1939.02270130011001","article-title":"Somnolence caused by hypothalamic lesions in the monkey","volume":"41","author":"Ranson","year":"1939","journal-title":"Arch. Neurol. Psychiatr."},{"key":"10.1016\/j.pbb.2024.173804_bb6000","first-page":"234","article-title":"Hyperinsulinism, narcolepsy and obesity\u2013an important clinical triad","volume":"10","author":"Roberts","year":"1962","journal-title":"Clin. Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0750","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/acsmedchemlett.3c00546","article-title":"Sulfonamide compounds as orexin receptor agonists for treating sleep disorders, namely, narcolepsy and hypersomnia","volume":"15","author":"Sabnis","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2024.173804_bb0755","article-title":"The present and future of synthetic orexin receptor agonists","volume":"171051","author":"Saitoh","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.pbb.2024.173804_bb0760","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pbb.2024.173804_bb0765","first-page":"183","article-title":"Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers","volume":"9","author":"Saletu","year":"1989","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0770","series-title":"AN 448 (42\u2013548): Drug Metabolism in Man., Unpublished Report","author":"Sandoz","year":"1972"},{"key":"10.1016\/j.pbb.2024.173804_bb0775","series-title":"AN 448 (42\u2013548): Drug Metabolism in Rats, Rabbits, Dogs, Rhesus Monkeys and Squirrel Monkeys","author":"Sandoz","year":"1972"},{"key":"10.1016\/j.pbb.2024.173804_bb0780","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jlac.18751790304","article-title":"Zur Kenntniss der Reihenfolge der Analgerung und Ausscheidung der Jodwasserstoffelemente in organischen Verbindungen","volume":"179","author":"Saytzeff","year":"1875","journal-title":"Justus Liebigs Ann. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0785","doi-asserted-by":"crossref","first-page":"77S","DOI":"10.1111\/j.1365-2125.1977.tb05763.x","article-title":"Studies on brain metabolism of biogenic amines","volume":"4","author":"Schacht","year":"1977","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0790","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0795","unstructured":"Schwartz, J.-C., Lecomte, J.-M., 2012. Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs. US Patent 8,106,041."},{"key":"10.1016\/j.pbb.2024.173804_bb0800","series-title":"Pharmacokinetic Studies with BLX-1026, a Novel Orexin-2 Receptor Agonist with Anti-Obesity Property, in Rats","author":"Sen","year":"2008"},{"key":"10.1016\/j.pbb.2024.173804_bb0805","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0021-5198(19)60301-X","article-title":"Mazindol, a non amphetaminergic appetite depressant, affects neuron activity in and control of gastric acid secretion by lateral and ventromedial hypothalamus","volume":"33","author":"Shiraishi","year":"1983","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0810","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0168-0102(98)82153-6","article-title":"Effects of leptin and orexins on the feeding behavior in rats","volume":"31","author":"Shiraishi","year":"1998","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0815","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0361-9230(85)90058-9","article-title":"Effects of mazindol on rat lateral hypothalamic neurons","volume":"15","author":"Sikdar","year":"1985","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2024.173804_bb0820","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0304-3940(03)00066-1","article-title":"Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat","volume":"341","author":"Smith","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"91","key":"10.1016\/j.pbb.2024.173804_bb0825","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF02976270","article-title":"Report on materia and therapeutics","volume":"1872-1920","author":"Smith","year":"1891","journal-title":"Dublin J. Med. Sci."},{"key":"10.1016\/j.pbb.2024.173804_bb0830","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0031-6989(73)80025-6","article-title":"Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate","volume":"5","author":"Spano","year":"1973","journal-title":"Pharmacol. Res. Commun."},{"key":"10.1016\/j.pbb.2024.173804_bb0835","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/S0960-894X(01)80838-6","article-title":"Unsymmetrically substituted guanidines as potent histamine H3-receptor antagonists","volume":"4","author":"Stark","year":"1994","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2024.173804_bb0840","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1521-4184(199806)331:6<211::AID-ARDP211>3.0.CO;2-P","article-title":"Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure","volume":"331","author":"Stark","year":"1998","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.pbb.2024.173804_bb0845","series-title":"King, F.D","first-page":"279","article-title":"6 the histamine H3 receptor and its ligands","author":"Stark","year":"2001"},{"key":"10.1016\/j.pbb.2024.173804_bb0850","series-title":"In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Sulfonamides","year":"2012"},{"key":"10.1016\/j.pbb.2024.173804_bb0855","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12272-021-01320-y","article-title":"Mechanistic diversity involved in the desensitization of G protein-coupled receptors","volume":"44","author":"Sun","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.pbb.2024.173804_bb0860","series-title":"Wake-Promoting Effects of Mazindol in Orexin Receptor 2 Knockout Mice","author":"Tafti","year":"2022"},{"key":"10.1016\/j.pbb.2024.173804_bb0865","first-page":"673","article-title":"Pharmacotherapy in narcolepsy. I. Eff","volume":"6","author":"Takahashi","year":"1964","journal-title":"Cent. Nerv. Syst. Stimul. Jpn. Clin Psychiatry"},{"key":"10.1016\/j.pbb.2024.173804_bb5000","author":"Temmler Werke"},{"key":"10.1016\/j.pbb.2024.173804_bb0870","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129555","article-title":"Neuronal antibodies in children with or without narcolepsy following H1N1-AS03 vaccination","volume":"10","author":"Thebault","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2024.173804_bb0875","series-title":"NLS Pharmaceutics: Quilience (Mazindol ER) a new approach for Type I & Type II narcolepsy: POLARIS clinical development program. Presented at the Satellite Symposium, World Sleep, March 11-16, Rome","author":"Thorpy","year":"2022"},{"key":"10.1016\/j.pbb.2024.173804_bb0880","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-444-52006-7.00001-0","article-title":"History of sleep medicine","author":"Thorpy","year":"2011","journal-title":"Handbook of Clinical Neurology. Elsevier"},{"key":"10.1016\/j.pbb.2024.173804_bb0885","article-title":"Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: analysis from the phase 3 REST-ON clinical trial","volume":"X 100113","author":"Thorpy","year":"2024","journal-title":"Sleep Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0890","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bph.14524","article-title":"Histamine pharmacology: from sir Henry Dale to the 21st century","volume":"177","author":"Tiligada","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173804_bb0895","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/00365521.1974.12096796","article-title":"Sulfonamide-induced chronic liver disease","volume":"9","author":"T\u00f6nder","year":"1974","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.pbb.2024.173804_bb0900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178526","article-title":"Orexin receptor agonist Yan 7874 is a weak agonist of orexin\/hypocretin receptors and shows orexin receptor-independent cytotoxicity","volume":"12","author":"Turku","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2024.173804_bb0905","series-title":"Connecting the Dots: An Updated Review of the Role of Autoimmunity in Narcolepsy and Emerging Immunotherapeutic Approaches","author":"Valizadeh","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0910","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cber.187300602191","article-title":"Eine neue Synthese der Alkohole","volume":"6","author":"Wagner","year":"1873","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"10.1016\/j.pbb.2024.173804_bb0915","series-title":"Novel Orexin Receptor Agonists Based on arene-or Pyridine-Fused 1, 3-Dihydro-2H-Imidazole-2-Imines","first-page":"129624","author":"Wang","year":"2024"},{"key":"10.1016\/j.pbb.2024.173804_bb0920","series-title":"Cathepsin H: molecular characteristics and clues to function and mechanism","first-page":"115585","author":"Wang","year":"2023"},{"key":"10.1016\/j.pbb.2024.173804_bb0925","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40263-018-0503-y","article-title":"A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of Mazindol in adults with DSM-5 attention-deficit\/hyperactivity disorder (ADHD)","volume":"32","author":"Wigal","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2024.173804_bb0930","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM197110282851802","article-title":"Treatment of intractable narcolepsy with a monoamine oxidase inhibitor","volume":"285","author":"Wyatt","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2024.173804_bb0935","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0013-4694(71)90147-7","article-title":"Effects of 5-hydroxytryptophan on the sleep of normal human subjects","volume":"30","author":"Wyatt","year":"1971","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.pbb.2024.173804_bb0940","unstructured":"Yates, S., Tedford, C., Brunden, K., 2004. Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity. US Patent 20040006120A1."},{"key":"10.1016\/j.pbb.2024.173804_bb0945","series-title":"Amer Chemical Soc 1155 16th ST, NW, Washington, DC 20036 USA","first-page":"U173","article-title":"Inverse agonists of the histamine 3 receptor as appetite suppressants","author":"Yates","year":"2003"},{"key":"10.1016\/j.pbb.2024.173804_bb0950","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1093\/sleepadvances\/zpad035.013","article-title":"O013 preliminary results from a phase 1 study of ALKS 2680, an Orexin-2 receptor agonist, in healthy participants and patients with narcolepsy or idiopathic hypersomnia","volume":"4","author":"Yee","year":"2023","journal-title":"Sleep Adv."},{"key":"10.1016\/j.pbb.2024.173804_bb0955","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1212\/WNL.9.3.171","article-title":"Treatment of narcolepsy with Ritalin","volume":"9","author":"Yoss","year":"1959","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2024.173804_bb0960","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0025-7125(16)32867-X","article-title":"On the treatment of narcolepsy","volume":"52","author":"Yoss","year":"1968","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.pbb.2024.173804_bb0965","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","article-title":"Discovery of arylsulfonamides as dual orexin receptor agonists","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173804_bb0970","unstructured":"Zwyer, A.C., Amsel, L.P., Schmith, V., Brantley, S., 2021. Mazindol IR\/SR multilayer tablet and its use for the treatment of attention deficit\/hyperactivity disorder (ADHD). Google Patents."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724000984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724000984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:08:15Z","timestamp":1719976095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305724000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":198,"alternative-id":["S0091305724000984"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173804","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From past to future: 50\u00a0years of pharmacological interventions to treat narcolepsy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"173804"}}